Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Open accessThe DOI matches its Crossref record; 80 of the 82 references it cites were found in a registry or an index.
Abstract
Checkpoint blockade immunotherapy targeting the PD-1/PD-L1 inhibitory axis has produced remarkable results in the treatment of several types of cancer. Whereas cytotoxic T cells are known to provide important antitumor effects during checkpoint blockade, certain cancers with low MHC expression are responsive to therapy, suggesting that other immune cell types may also play a role. Here, we employed several mouse models of cancer to investigate the effect of PD-1/PD-L1 blockade on NK cells, a population of cytotoxic innate lymphocytes that also mediate antitumor immunity. We discovered that PD-1 and PD-L1 blockade elicited a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy. PD-1 was expressed on NK cells within transplantable, spontaneous, and genetically induced mouse tumor models, and PD-L1 expression in cancer cells resulted in reduced NK cell responses and generation of more aggressive tumors in vivo. PD-1 expression was more abundant on NK cells with an activated and more responsive phenotype and did not mark NK cells with an exhausted phenotype. These results demonstrate the importance of the PD-1/PD-L1 axis in inhibiting NK cell responses in vivo and reveal that NK cells, in addition to T cells, mediate the effect of PD-1/PD-L1 blockade immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 (a.k.a. CD279) is expressed on activated T cells as well as other cells including but not limited to B cells, natural killer (NK) cells, and myeloid cells (Hsu et al., 2018; Nam et al., 2019).”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Hsu et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kohrt, H. E., Houot, R., Weiskopf, K., Goldstein, M. J., Scheeren, F., Czerwinski, D., Colevas, A. D., Weng, W.-K., Clarke, M. F., Carlson, R. W., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci61226 · Cited by 226
RetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Cited by
Items 501–600 of 848
The Roles of Natural Killer Cells in Breast Cancer Pathobiology and Their Regulation by Estrogens
Byemerwa, J. K., Chang, C., & McDonnell, D. P. (2025) · Endocrine Reviews · doi:10.1210/endrev/bnaf014 · Cited by 11
Sun, H., Huang, D., Zhang, H., Dong, M., Wang, S., Sun, M., Liu, J., Wang, Y., Qu, X., Li, X., et al. (2025) · MedComm – Oncology · doi:10.1002/mog2.70030 · Cited by 13
CAR-NK Engineering to Overcome TME Barriers
Islam, F., Pupovac, A., Boyd, R. L., & Trounson, A. O. (2025) · Cells · doi:10.3390/cells15010021 · Cited by 11
“PD-1 is abundantly expressed on activated NK cells, and upon ligation with the PD-L1 receptor overexpressed in tumor cells, leads to immunosuppression, thereby impairing NK cell functionality [134].”
An overview of some potential immunotherapeutic options against COVID-19
Bayat, M., Asemani, Y., Mohammadi, M. R., Sanaei, M., Namvarpour, M., & Eftekhari, R. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107516 · Cited by 12
Luo, B., Zhang, S., Tan, D., Yu, X., Lin, J., & Wang, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/8965903 · Cited by 13
“The collective clinical evidence to date suggests that ICIs are most e ff ective in in fl amed tumors as characterized by tumor PD-L1 expression, high CD8+ T cell density, or the presence of a strong IFN-γ cytolytic T cell signature [24 – 26].”
InfluentialGeneration of a symmetrical trispecific NK cell engager based on a two-in-one antibody
Harwardt, J., Carrara, S. C., Bogen, J. P., Schoenfeld, K., Grzeschik, J., Hock, B. M., & Kolmar, H. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170042 · Cited by 11
“Moreover, NK cell activity can be negatively affected by immune checkpoints such as PD-1/PD-L1 axis (26).”
BackgroundLiao, K., Yang, Q., Xu, Y., He, Y., Wang, J., Li, Z., Wu, C., Hu, J., & Wang, X. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109811 · Cited by 12
Luo, H., Yang, C., Kuang, D., Shi, S., & Chan, A. W. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05680-5 · Cited by 11
“Furthermore, evidence that PD-1 can be expressed on the surface of human NK cells has recently appeared in various cancer types, including NSCLC [28], and PD-L1 blockade enhances the anti-tumor efficacy of NK cells [29].”
BackgroundPugh-Toole, M., Nicolela, A. P., Nersesian, S., Leung, B. M., & Boudreau, J. E. (2022) · Current Treatment Options in Oncology · doi:10.1007/s11864-021-00929-x · Cited by 11
“Existing immunotherapies may benefit from strategies to mobilize NK cell anticancer activity Like T cells, NK cells are sensitive to immunologic checkpoint-mediated inhibition [43].”
BackgroundThe RNA helicase DHX15 is a critical regulator of natural killer-cell homeostasis and functions
Wang, G., Xiao, X., Wang, Y., Chu, X., Dou, Y., Minze, L. J., Ghobrial, R. M., Zhang, Z., & Li, X. C. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00852-7 · Cited by 14
“Deletion of Dhx15 in NK cells altered tumor surveillance and metastasis in vivo As NK cells are critical for the control of certain tumor cells in vivo [43, 44], we utilized the B16F10 melanoma model, an extensively characterized model of tumor metastasis that is controlled by NK cells [45], to further determine the f…”
MethodHarnessing the Power of NK Cell Receptor Engineering as a New Prospect in Cancer Immunotherapy
Douka, S., Papamoschou, V., Raimo, M., Mastrobattista, E., & Caiazzo, M. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091143 · Cited by 11
“Hsu and colleagues demonstrated within their in vivo mouse studies that inhibition of PD-1 or PD-L1 can stimulate NK cell activity [39,136].”
BackgroundImmune microenvironment of cancer bone metastasis
Hiraga, T. (2024) · Bone · doi:10.1016/j.bone.2024.117328 · Cited by 14
IRF4 expression by NK precursors predetermines exhaustion of NK cells during tumor metastasis
Zhang, X., Yin, Z., Wu, J., Xiao, X., Zou, D., Wang, G., Fu, J., Lan, P., Minze, L. J., Li, X. C., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02176-w · Cited by 11
“However, the role of PD-1 is complex, as its expression has also been associated with NK cell activation, not solely exhaustion 37 .”
Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours
Doeppner, C. A., Binder, A. K., Bremm, F., Feuchter, N., Dörrie, J., & Schaft, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136290 · Cited by 10
“Blocking PD-1 or PD-L1 has been demonstrated to restore NK-cell function, promote proliferation, and enhance cytotoxic activity against PD-L1 + tumours [145,146].”
“Built‐in” PD‐1 blocker to rescue NK‐92 activity from PD‐L1–mediated tumor escape mechanisms
Mensali, N., Dillard, P., Fayzullin, A., Köksal, H., Gaudernack, G., Kvalheim, G., Inderberg, E. M., & Wälchli, S. (2021) · The FASEB Journal · doi:10.1096/fj.202100025r · Cited by 10
Kravtsova‐Ivantsiv, Y., Goldhirsh, G., Tomuleasa, C., Pikarsky, E., & Ciechanover, A. J. (2023) · Cancer Cell International · doi:10.1186/s12935-023-02919-5 · Cited by 10
“Accordingly, blocking the PD-1/PD-L1 axis triggers a potent anti-tumoral activity of natural killer (NK) cells [23].”
BackgroundMou, J., Xie, L., Xu, Y., Zhou, T., Liu, Y., Huang, Q., Tang, K., Tian, Z., Xing, H., Qiu, S., et al. (2023) · Cytotherapy · doi:10.1016/j.jcyt.2023.07.002 · Cited by 10
Update on Radiotherapy Changes of Nasopharyngeal Carcinoma Tumor Microenvironment
Zhu, D., Su, C., Li, J. J., Li, A. W., Luv, Y., & Fan, Q. (2023) · World Journal of Oncology · doi:10.14740/wjon1645 · Cited by 10
“Effective NK cell anti-tumor activity has been shown to be a prerequisite for T-cell-mediated anti-tumor immune responses [20].”
BackgroundDeng, R., Tian, R., Li, X., Xu, Y., Li, Y., Wang, X., Li, H., Wang, L., Xu, B., Yang, D., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109533 · Cited by 11
Núñez, S. Y., Trotta, A., Regge, M. V., Amarilla, M. S., Secchiari, F., Sierra, J. M., Santilli, M. C., Gantov, M., Rovegno, A. R., Richards, N., et al. (2024) · European Journal of Immunology · doi:10.1002/eji.202350878 · Cited by 14
“In addition, TAM depletion resulted in a higher expression of the activating receptor NKG2D, accompanied by a reduced frequency of TINK that express PD-1 and TIM-3 exhaustion-associated molecule [34–37].”
BackgroundNegative regulation of innate lymphoid cell responses in inflammation and cancer
Sciumè, G., Fionda, C., Stabile, H., Gismondi, A., & Santoni, A. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.01.011 · Cited by 10
Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer
Want, M. Y., Karasik, E., Gillard, B. M., McGray, A. R., & Battaglia, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168742 · Cited by 10
“Interestingly, recent studies indicate that NK cells appear to benefit from checkpoint blockade therapy, with NK cell responses having a fundamental role in generating maximal anti-tumor immunity [43].”
BackgroundThe role of NK cells in oncolytic viral therapy: a focus on hepatocellular carcinoma
Warricker, F., Khakoo, S. I., & Blunt, M. D. (2021) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2021.27 · Cited by 19
Lin, A., Xu, W., Luo, P., & Zhang, J. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.721181 · Cited by 10
Russo, G. L., Sgambelluri, F., Prelaj, A., Galli, F., Manglaviti, S., Bottiglieri, A., di Mauro, R. M., Ferrara, R., Galli, G., Signorelli, D., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100645 · Cited by 11
“In pre-clinical models, Hsu et al.21 found that PD-1 and PD-L1 blockade promotes an NK cell response that is essential for the efficacy of immunotherapy.”
MethodLiu, M., Sun, Q., Wei, F., & Ren, X. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0112 · Cited by 10
Immune Cells in Hyperprogressive Disease under Immune Checkpoint-Based Immunotherapy
Wei, Z., & Zhang, Y. (2022) · Cells · doi:10.3390/cells11111758 · Cited by 10
“generation of powerful T cells but also restore antitumor responses in NK cells [117,133].”
BackgroundPersky, J., Cruz, S. M., Darrow, M. A., Judge, S. J., Li, Y., Bold, R. J., Karnezis, A. N., Matsukuma, K. E., Qi, L., & Canter, R. J. (2024) · Journal of Surgical Oncology · doi:10.1002/jso.27581 · Cited by 10
“11,29,30 Although it is possible that our study and others like it are underpowered to show an association between NK infiltrates and outcomes in PDAC surgical specimens, the discrepancy in results between preclinical studies showing an association of NK cells with antitumor responses in PDAC in…”
ResultRegulation of NK cell development, maturation, and antitumor responses by the nuclear receptor NR2F6
Woelk, J., Hornsteiner, F., Wallner, S., Stoitzner, P., Baier, G., & Hermann‐Kleiter, N. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07407-4 · Cited by 9
Zou, M., Qattan, A. T., Al-Alwan, M. M., Ghebeh, H., Binjumah, N., Al‐Haj, L., Khabar, K. S. A., Altaweel, A., Almohanna, F., Assiri, A. M., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1514264 · Cited by 11
“PD-1/PD-L1 blockade enhances anti-tumor ef fi cacy of NK cells (41, 42).”
IL-18-primed NK cells recruit dendritic cells and potentiate tumor therapy mediated by PD-1 blockade
Ohno, Y., Okamura, H., Yagita∥, H., & Tanaka, T. T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1533808 · Cited by 10
LAG3 Marks Activated but Hyporesponsive NK Cells
Vasilyeva, V., Makinson, O., Chan, C. S. Y., Park, M., O’Dwyer, C., Ali, A., Khan, A. U. H., de Souza, C. T., Hasim, M. S., Asif, S., et al. (2025) · European Journal of Immunology · doi:10.1002/eji.70009 · Cited by 12
Self-citationFelices, M., Wesley, E., Bendzick, L. E., Kodal, B., Hopps, R., Grzywacz, B. J., Hinderlie, P., Miller, J. S., & Geller, M. A. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-22-0600 · Cited by 10
Electroacupuncture targeting the immune system to alleviate sepsis
Fang, M., Lan, Y., Li, M., Li, C., Xu, B., Ma, Y., Noiprasert, S., Jing, X., & Yu, L. (2024) · Acupuncture and Herbal Medicine · doi:10.1097/hm9.0000000000000092 · Cited by 10
“The important immunosuppressive checkpoint regulator programmed death protein 1 (PD-1), which is largely produced by activated T cells, was first identified in T-cell lymphoma [57] and initiated the process of T-cell death.”
BackgroundYuan, H., Bai, Y., Gu, D., Wang, P., Sun, X., Yang, J., Wong, Y. K., Huang, W., Wang, X., Ma, J., et al. (2024) · Nano Today · doi:10.1016/j.nantod.2024.102419 · Cited by 9
Su, M., Zhang, Z., Jiang, P., Wang, X., Tong, X., & Wu, G. (2024) · Cell Transplantation · doi:10.1177/09636897241293964 · Cited by 9
Guiteras, J., de Ramón, L., Crespo, E., Bolaños, N., Barceló-Batllori, S., Martínez-Valenzuela, L., Fontova, P., Jarque, M., Torija, A., Bestard, O., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031216 · Cited by 9
Ashoori, M. D., Suzuki, K., Tokumaru, Y., Ikuta, N., Tajima, M., Honjo, T., & Ohta, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.618711 · Cited by 10
Zhong, Z., Wang, J., Han, Q., Lin, H., Luo, H., Guo, D., Jiang, Y., & Liu, A. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.969536 · Cited by 9
“combination of B cell-promoting and PD1-blocking therapies could provide antitumor effects owing to synergistic effects on B and NK cells (Hsu et al., 2018; Sanchez-Correa et al., 2019).”
BackgroundVeinalde, R., Pidelaserra-Martí, G., Moulin, C., Tan, C. L., Schäfer, T. E., Kang, N. H., Ball, C. R., Leichsenring, J., Stenzinger, A., Kaderali, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1096162 · Cited by 10
“Since natural killer (NK) cells have also been implicated in response to PD-1/PD-L1 checkpoint blockade (29), the relative abundance of CD335+ and activated CD335+”
BackgroundWang, X., Liu, X., Dai, H., & Jia, J. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03168-0 · Cited by 9
“The anti tumor activity of NK cells is one of the bases for the efficacy of PD-1 /PD-L1 inhibitors [36].”
BackgroundA cytofluorimetric assay to evaluate intracellular cytokine production by NK cells
Sordo‐Bahamonde, C., Lorenzo‐Herrero, S., Gonzalez, S. R., & López‐Soto, A. (2019) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2019.05.049 · Cited by 9
Zhang, B., Song, Y., Luo, S., Yin, X., Li, E., Wang, H., He, Y., Liu, Z., Fan, Q., Liang, X., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101301 · Cited by 9
Mechanisms of primary resistance to immune checkpoint inhibitors in NSCLC
Gomatou, G., Charpidou, A. G., Li, P., Syrigos, N. K., & Gkiozos, I. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03731-x · Cited by 10
“Furthermore, treatment with PD-1 and PD-L1 blockade in a preclinical model led to a strong NK cell response that was indispensable for the full therapeutic effect of immunotherapy, conversely low levels of NK cells contributed to primary resistance in immunotherapy [72].”
Hong, S., Su, Z., Zhang, Y., Hu, G., Zhang, Q., Ji, Z., Wang, L., Yu, S., Zhu, X., Yuan, F., et al. (2024) · Environmental Science & Technology · doi:10.1021/acs.est.4c06411 · Cited by 8
Myers, J. A., Huang, R., Phung, S. K., Chacón, J. M., Bendzick, L. E., Weis, A., Shetty, M., DePauw, T. A., Khaw, M. J., Abrahante, J. E., et al. (2025) · Blood · doi:10.1182/blood.2024027763 · Cited by 8
Kawczak, P., Feszak, I. J., & Bączek, T. (2025) · Cancers · doi:10.3390/cancers17172805 · Cited by 9
“Anti-angiogenic drugs can normalize vasculature and improve immune cell infiltration [416].”
Natural Killer Cell Epigenetic Reprogramming in Tumors and Potential for Cancer Immunotherapy
Hojjatipour, T., Maali, A., & Azad, M. (2023) · Epigenomics · doi:10.2217/epi-2022-0454 · Cited by 8
Impact and potential value of immunosenescence on solid gastrointestinal tumors
Zhang, T., Wen, R., Fan, H., Yu, Y., Jia, H., Peng, Z., Zhou, L., Yu, G., & Zhang, W. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1375730 · Cited by 11
Hurtado, M., Khajavi, L., Essabbar, A., Kammer, M. N., Xie, T., Coullomb, A., Pradines, A., Casanova, A., Kruczynski, A., Gouin, S., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1394965 · Cited by 8
Lipid-based polymeric biomaterial-mediated ex vivo natural killer cell surface engineering
Park, J., Noh, K. M., & Kim, K. (2025) · Biomaterials Science · doi:10.1039/d5bm00692a · Cited by 8
Ouyang, R., Li, Z., Peng, P., Zhang, J., Li, J., Qin, M., & Huang, J. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.51918 · Cited by 13
“A previous study conducted on mouse model showed that the depletion of NK cells eliminated the PD-1 ligand inhibition functions [32].”
Corominas, J. M., Sapena, V., Sanduzzi‐Zamparelli, M., Millán, C., Samper, E., Llarch, N., Iserte, G., Torres, F., da Fonseca, L. G., Muñoz, S., et al. (2021) · Cancers · doi:10.3390/cancers13030426 · Cited by 9
NK cells seize PD1 from leukaemia cells
Newman, J. H., & Horowitz, A. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00562-7 · Cited by 8
Dunai, C., Ames, E., Ochoa, M. C., Fernández-Sendin, M., Melero, I., Simonetta, F., Baker, J. B., & Álvarez, M. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.001 · Cited by 8
Lin, C., Horwitz, M. E., & Rein, L. A. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms24010204 · Cited by 8
Multifaceted nature of natural killer cells: Potential mode of interaction and shaping of stem cells
Senjor, E., Ko, M.-W., Kaur, K., Chen, P.-C., Breznik, B., Chovatiya, N., Kos, J., & Jewett, A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822620-9.00020-3 · Cited by 10
Facing challenges with hope: universal immune cells for hematologic malignancies
Wang, Y., Huang, R., Wang, Z., Xiong, J., Wang, X., & Zhang, X. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2022.0759 · Cited by 8
Sun, Y., Malaer, J. D., & Mathew, P. A. (2019) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2019.29 · Cited by 8
“Blockade of PD-1 and PDL-1 with mAb results in the strong NK cell responses required for full immunotherapeutic effect[42].”
BackgroundZhang, H., Zhu, Y., Wang, J., Weng, S., Zuo, F., Li, C., & Zhu, T. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110115 · Cited by 8
Potential Application of Small Interfering RNA in Gastro-Intestinal Tumors
Losurdo, P., de Manzini, N., Palmisano, S., Grassi, M., Parisi, S., Rizzolio, F., Tierno, D., Biasin, A., Grassi, C., Truong, N. H., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15101295 · Cited by 9
“While PD-1 is mostly expressed on the surface of immune cells, PD-L1 is predominately expressed by tumor cells [101].”
BackgroundIshii, K., Shimizu, M., Kogo, H., Negishi, Y., Tamura, H., Morita, R., & Takahashi, H. (2019) · Immunobiology · doi:10.1016/j.imbio.2019.10.009 · Cited by 8
Santagata, S., Trotta, A. M., D’Alterio, C., Napolitano, M., Rea, G., Napoli, M. D., Portella, L., Ieranò, C., Guardascione, G., Coppola, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0729 · Cited by 7
“The role of PD1 on NKs is controversial, as PD1+ NKs have been reported as both functionally defective (27, 29) or activated (30, 31) cells.”
Genome editing of immune checkpoints: CRISPR-mediated PD-1 inhibition in cancer
Mohammad, S. I. S., Kareem, A. K., Vasudevan, A., Rekha, M. M., Jabir, M. S., Nayak, P. P., AlKhafaje, Z., Arora, V., Kadhum, W. R., & Chennakesavulu, K. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152438 · Cited by 7
Vredevoogd, D. W., Apriamashvili, G., & Peeper, D. S. (2021) · Immuno-Oncology Technology · doi:10.1016/j.iotech.2021.100043 · Cited by 8
“Firstly, IFN-g-induced programmed death-ligand 1 (PD-L1), arguably the most prominent IFN-g-mediated immune evasion mechanism and well-established therapeutic target,(15,98-100) binds to its receptor PD-1 on multiple immune cells and inhibits their activities.(74,98,99,101) As discussed above, IFN-g also elevates the…”
BackgroundThe inhibitory NKR-P1B receptor regulates NK cell-mediated mammary tumor immunosurveillance in mice
Olabi, R. A., Hendy, A. E. A., Alkassab, M. B., Alnajm, K., Elias, M., Ibrahim, M., Carlyle, J. R., Makrigiannis, A. P., & Rahim, M. M. A. (2023) · OncoImmunology · doi:10.1080/2162402x.2023.2168233 · Cited by 7
“have shown that immune checkpoint receptor blockade (ICB) can improve NK cell functions and enhance their anti-cancer activity.(41,42,46) NK cells exhibit dysfunctional states similar to T cells, which can be resolved by ICB, but the nature of the”
BackgroundKwaśnik, P., Zaleska, J., Link-Lenczowska, D., Zawada, M., Wysogląd, H., Ochrem, B., Bober, G., Wasilewska, E. M., Hus, I., Szarejko, M., et al. (2024) · Cells · doi:10.3390/cells13080723 · Cited by 9
“PD-1/PD-L1 blockade could restore specific functions of the CD8 + CTL or NK that might be important in controlling CML progression [20,22].”
BackgroundRosnev, S., Sterner, B., Schiele, P., Kolling, S., Martin, M., Flörcken, A., Erber, B., Wittenbecher, F., Kofla, G., Kurreck, A., et al. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115252 · Cited by 7
PARP inhibition elicits NK cell-associated immune evasion via potentiating HLA-G expression in tumor
Wang, S., Xia, Y., Qian, Y., Pan, W., Huang, P., Jin, N., Li, X., Xu, C., Liu, D., Zhao, G., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101247 · Cited by 8
McLaughlin, Q., Sojka, D. K., Kennedy, K. J., Piersma, S. J., & Sethakorn, N. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03503-7 · Cited by 8
“These immune checkpoints are generally considered to be targeting T cell immunity, but PD1 has been associated with NK cell tumor immunity as well [188], including NSCLC [189].”
Natural Killer Cell-targeted Immunotherapy for Cancer
Tang, J., Zhu, Q., Li, Z., Yang, J., & Lai, Y. (2022) · Current Stem Cell Research & Therapy · doi:10.2174/1574888x17666220107101722 · Cited by 7
Nelli, F., Signorelli, C., Fabbri, A., Giannarelli, D., Virtuoso, A., Berrìos, J. R. G., Marrucci, E., Fiore, C., Schirripa, M., Chilelli, M. G., et al. (2023) · Cancers · doi:10.3390/cancers15143625 · Cited by 7
“NK cells play an essential role in the development of anti-cancer immunity [41].”
BackgroundPesini, C., Artal, L., Bernal, J. P., Sánchez‐Martínez, D., Pardo, J., & Ramírez-Labrada, A. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2379062 · Cited by 8
Miązek-Zapała, N., Ślusarczyk, A., Kusowska, A., Zapała, P., Kubacz, M., Winiarska, M., & Bobrowicz, M. (2021) · Cells · doi:10.3390/cells10061511 · Cited by 8
Cutshaw, G., Kothadiya, S., Uthaman, S., Pandya, D. N., Wen, X., Mathew, A. P., Sinha, A., Antony, I., Vilgelm, A. E., Wadas, T. J., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c11312 · Cited by 6
Huang, M., Wang, S., Huang, H., Li, L., & Wang, T. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1705354 · Cited by 7
Pan, J., Chen, S., Jin, L., Chen, K., Ye, Z., & Li, B. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189544 · Cited by 8
Immune Exhaustion in Chronic Infection and Cancer: Signaling Pathways and Therapeutic Interventions
Song, Y., Mo, Y., Chen, S., Chen, Y., Zhang, C., Deng, S., Liao, J. Q., He, Y., Wang, W., Zheng, W., et al. (2026) · MedComm · doi:10.1002/mco2.70635 · Cited by 7
“This complexity accounts for the conflicting reports regarding PD-1 levels on exhausted cells [ 94 ].”
Láníčková, T., Angelidou, A., Hensler, M., Vankerckhoven, A., Niederlová, V., Vošáhlíková, Š., Kašíková, L., Bock, A., Zacharova, E., Stekas, C., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72036-0 · Cited by 6
Seon, B. K., Okazaki, M., Duzen, J. M., Matsuno, F., Goey, A. K. L., & Maguire, O. (2024) · Leukemia Research · doi:10.1016/j.leukres.2024.107436 · Cited by 6
Diao, J., Wei, Z., Pei, Y., Ge, J., Qing, Y., Wei, Y., Chen, Y., & Peng, X. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03885-1 · Cited by 6
“In cancer mouse models, it is found that activated NK cells can express PD-1 and PD-1 engagement by PD-L1 on tumor cells can suppress anti-tumor mediated by NK cells [23].”
Desbois, M., Giffon, T. D., Yakkundi, P., Denson, C. R., Sekar, K., Hart, K. C., dos Santos, D. M., Calhoun, S. E., Logronio, K. A., Pandey, S., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0937 · Cited by 6
“We cannot rule out that some activity observed in the IGM-7354 and daratumumab combination is derived from PD-1/PD-L1 pathway blockade given that mouse PD-1 can bind to human PD-L1 (54) and that antitumor responses can be restored by blocking the PD-1/PD-L1 axis on NK cells (55).”
Liu, K., Hoover, A. R., Sun, Y., Valerio, T. I., Furrer, C. L., Adams, J. P., Wang, L., Naqash, A. R., & Chen, W. R. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217825 · Cited by 8
Hoffmann, C., Filali, L., Wurzer, H., Fernandes, D. P., Mgrditchian, T., Huang, W., Moreau, F., Krecké, M., & Thomas, C. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2503259122 · Cited by 6
Strategies for the Development of NK Cell-Based Therapies for Cancer Treatment
Budagova, T., Efremova, A. S., Maiak, M. A., & Goldshtein, D. V. (2025) · Cells · doi:10.3390/cells14231858 · Cited by 6
“These PD-1-positive NK cells also have a low level of expression of activating receptors, such as NKG2D, NKp30, NKp46, and DNAM-1, and reduced secretion of IFN γ , TNF-α , and granzymes [111,112].”
A logic-gated trispecific engager enhances macrophage killing of cancer cells in solid tumors
Zhao, X., Jing, W., Wang, G., Liu, Z., Xu, X., Han, M., Fu, Z., Zhang, Y., Zheng, Z., Zhang, J., et al. (2026) · Nature Biotechnology · doi:10.1038/s41587-026-03057-9 · Cited by 7
Li, C., Zhu, Z., Hou, Q., Wang, B., Zou, L., Liu, L., Gong, W., & Guo, H. (2021) · Translational Cancer Research · doi:10.21037/tcr-21-2380 · Cited by 6
“This proved that NK cells are involved in the therapeutic effect of PD-1/PD-L1 blockade (32).”
BackgroundNovel extracellular role of REIC/Dkk-3 protein in PD-L1 regulation in cancer cells
Gohara, Y., Tomonobu, N., Kinoshita, R., Futami, J., Audebert, L., Chen, Y., Komalasari, N. L. G. Y., Jiang, F., Yoshizawa, C., Murata, H., et al. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02292-w · Cited by 6
“After 36 h, these cells were lysed and pulldowned for the expressed foreign CXCR6, and the precipitated specimens were subjected to SDS-PAGE and then silver staining. b A band for a protein that bound with CXCR6 and whose binding was diminished by the presence of REIC/Dkk-3 was subjected to a liquid chromatography-tan…”
BackgroundInfluentialFc Receptor is Involved in Nk Cell Functional Anergy Induced by Miapaca2 Tumor Cell Line
Ostapchuk, Y. O., Perfilyeva, Y. V., Kali, A., Tleulieva, R., Yurikova, O. Y., Stanbekova, G. E., Каральник, Б. В., & Belyaev, N. N. (2020) · Immunological Investigations · doi:10.1080/08820139.2020.1813757 · Cited by 6
“The importance of the PD1/PDL1 axis in inhibiting NK cell responses including impaired granule polarization and IFNγ production has been demonstrated earlier (Hsu et al. 2018; Li et al. 2014; Liu et al. 2013).”
BackgroundLee, Y. S., Heo, W., Choi, H.-J., Cho, H.-R., Nam, J. H., Ki, Y. G., Lee, H.-R., Son, W.-C., Park, Y.-S., Kang, C., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0248870 · Cited by 6
“NK cells are critical innate immune lymphocytes to destroy virally infected or cancerous cells through targeted cytotoxicity [12].”
BackgroundGalván-Morales, M. Á., Rodríguez, R. B., Cruz, J. R. S., & Teran, L. M. (2021) · Vide Leaf, Hyderabad eBooks · doi:10.37247/pamol2ed.2.2021.5 · Cited by 6
Emerging hallmark of gliomas microenvironment in evading immunity: a basic concept
Arifianto, M. R., Meizikri, R., Haq, I. B. I., Susilo, R. I., Wahyuhadi, J., Hermanto, Y., & Faried, A. (2023) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-023-00635-5 · Cited by 7
“Although the number of NK cells in GBMs is deemed low, they retained cytotoxic activity [80].”
BackgroundThe Emerging Role of NK Cells in Immune Checkpoint Blockade
Martínez‐Pérez, A., Aguilar-García, C., & Gonzalez, S. R. (2022) · Cancers · doi:10.3390/cancers14236005 · Cited by 6
“Downregulation of HLA class I is a mechanism frequently developed by certain cancers, such as Hodgkin’s lymphoma, to avoid T cell recognition; however, these cancer cells are more efficiently identified and eliminated by NK cells (missing-self recognition) [16].”
BackgroundNK cells link immune-checkpoint blockade immunotherapy and response in melanoma brain metastases
Kohanbash, G., Frederico, S. C., & Raphael, I. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-011581 · Cited by 6
“7 Taggart et al demonstrated in preclinical studies using a dual tumor melanoma BM model that PD-1/CTLA-4 ICB efficacy is dependent on CD8 T cells and NK cells.”
Martinović, K. M., Vuletić, A., Miletić, N. T., Nedeljković, M., Matković, S., & Jurišić, V. (2025) · Clinical Immunology · doi:10.1016/j.clim.2025.110557 · Cited by 5
A Perspective on the CD47-SIRPA Axis in High-Risk Neuroblastoma
Tang, X. X., Shimada, H., & Ikegaki, N. (2024) · Current Oncology · doi:10.3390/curroncol31060243 · Cited by 5
“Consistent with these observations, high-risk neuroblastoma cells do not express the immune checkpoint molecule PD-L1 [5] that controls the activity of PD-1 positive CD8+ T and NK cells [7,8].”
ResultEpigenetic modulation elicits an NK cell-mediated immune response in urothelial carcinoma
Kumari, H., Chen, C.-N., Shih, H.-A., Yeh, C.-C., Tseng, T.-Y., Tsai, H.-F., Low, J. T., Chan, C. P., Lin, G., Huang, W.-H., et al. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01264-9 · Cited by 5
Hawi, G., Kim, P., & Lee, P. P. (2025) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2025.112231 · Cited by 5
Hepatocellular carcinoma and liver transplant: What about neo- and adjuvant immunotherapy
Khalaf, M. H., Tran, B. V., Krendl, F. J., Doan, T., Rachko, J., Marino, R., & Tabrizian, P. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.10.004 · Cited by 8
Next-generation immune cell therapies for lung cancer: advances in CAR-T, NK, and TIL strategies
Khan, A., Mujahid, A., Tareen, A., Amin, A., Khan, S. R., Hadi, D. K., & Raza, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1787086 · Cited by 6
“Patients who responded clinically also exhibited increased levels of activated NK cells (CD56 bright , CD94 /NKG2D ) in their peripheral blood (54).”
Influential
Metadata
- Authors
- Hsu, J., Hodgins, J. J., Marathe, M., Nicolai, C. J., Bourgeois-Daigneault, M.-C., Trevino, T. N., Azimi, C. S., Scheer, A. K., Randolph, H. E., Thompson, T. W., Zhang, L., Iannello, A., Mathur, N., Jardine, K. E., Kirn, G. A., Bell, J. C., McBurney, M. W., Raulet, D. H., & Ardolino, M.
- Affiliations
- University of California, Berkeley (US)
- University of Ottawa (CA)
- Corresponding author
- Raulet, David H.
- Ardolino, Michele
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-09-10
- Volume
- 128
- Issue
- 10
- Pages
- 4654-4668
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6159991
- OpenAlex
- W2890056446
- Cited by
- 817
- References
- 82
- Citations by year
- 2026: 57 · 2025: 96 · 2024: 107 · 2023: 101 · 2022: 106 · 2021: 148 · 2020: 124 · 2019: 68 · 2018: 7
- FWCI
- 37.29
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- Canadian Institutes of Health Research
- National Cancer Institute (R01CA093678)
- National Institute of General Medical Sciences (T32GM007232)
- National Institute of Allergy and Infectious Diseases (R01AI113041)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- natural killer cells, PD-1, PD-L1, immune checkpoint blockade, cancer immunotherapy, NK cell exhaustion, antitumor immunity, NK cell activation, tumor immunosuppression, MHC expression
- MeSH terms
- Animals, Humans, Immunotherapy, Killer Cells, Natural, Neoplasms, Experimental, Mice, Knockout, K562 Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.